Other · developed by Lantheus Medical Imaging
LMI 1195 is an agent given as a single bolus intravenous injection. It has been studied in heart failure.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00891241 | Phase 1 | Heart Failure | Completed | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Heart Failure
Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →